303 related articles for article (PubMed ID: 16234566)
21. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
22. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.
Arvold ND; Chen MH; Moul JW; Moran BJ; Dosoretz DE; Bañez LL; Katin MJ; Braccioforte MH; D'Amico AV
J Urol; 2011 Jul; 186(1):91-6. PubMed ID: 21571341
[TBL] [Abstract][Full Text] [Related]
23. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
[TBL] [Abstract][Full Text] [Related]
24. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
Siddiqui SA; Inman BA; Sengupta S; Slezak JM; Bergstralh EJ; Leibovich BC; Zincke H; Blute ML
Cancer; 2006 Aug; 107(3):521-9. PubMed ID: 16773619
[TBL] [Abstract][Full Text] [Related]
25. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
26. Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of hospital episodes statistics for England.
Judge A; Evans S; Gunnell DJ; Albertsen PC; Verne J; Martin RM
BJU Int; 2007 Nov; 100(5):1040-9. PubMed ID: 17784890
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
[TBL] [Abstract][Full Text] [Related]
28. Changes in continence and erectile function between 2 and 4 years after radical prostatectomy.
Glickman L; Godoy G; Lepor H
J Urol; 2009 Feb; 181(2):731-5. PubMed ID: 19091349
[TBL] [Abstract][Full Text] [Related]
29. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
[TBL] [Abstract][Full Text] [Related]
30. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
31. Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy.
Froehner M; Koch R; Litz RJ; Haase M; Klenk U; Oehlschlaeger S; Baretton GB; Wirth MP
Scand J Urol Nephrol; 2005; 39(6):449-54. PubMed ID: 16303719
[TBL] [Abstract][Full Text] [Related]
32. Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: results from the 100% Medicare sample.
Kowalczyk KJ; Levy JM; Caplan CF; Lipsitz SR; Yu HY; Gu X; Hu JC
Eur Urol; 2012 Apr; 61(4):803-9. PubMed ID: 22209053
[TBL] [Abstract][Full Text] [Related]
33. Interaction between age and comorbidity as predictors of mortality after radical prostatectomy.
Froehner M; Koch R; Litz RJ; Hakenberg OW; Oehlschlaeger S; Wirth MP
J Urol; 2008 May; 179(5):1823-9; discussion 1829. PubMed ID: 18355873
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
36. Postoperative inguinal hernia after radical prostatectomy for prostate cancer.
Abe T; Shinohara N; Harabayashi T; Sazawa A; Suzuki S; Kawarada Y; Nonomura K
Urology; 2007 Feb; 69(2):326-9. PubMed ID: 17275071
[TBL] [Abstract][Full Text] [Related]
37. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer.
Liu L; Coker AL; Du XL; Cormier JN; Ford CE; Fang S
J Surg Oncol; 2008 Jun; 97(7):583-91. PubMed ID: 18381603
[TBL] [Abstract][Full Text] [Related]
39. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
40. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
